drugset

drugset / Trial / NCT03131999

LAM Pilot Study With Imatinib Mesylate

NCT03131999 ↗

Phase 1/2 Completed 18 enrolled Medical University of South Carolina Columbia University · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).

Timeline

Start: 2018-01-23
Primary completion: 2019-03-07
Completion: 2019-03-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	Oral

Indications